|
|
14, rue de la Colombiäre
Nyon, 1260 Switzerlad
phone:011-41-22-363-13-10
fax:011-41-22-363-13-11
|
|
| Symbol |
MYMX |
| Exchange |
OTCBB |
| Founded |
1991 |
| Employees |
|
|
|
| www.mymetics.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Mymetics is a biotechnology company developing vaccines and therapies to treat AIDS. |
|
| Management |
| Christian J.-F. Rochet, President, Chief Executive Officer, Director; Ernst Lbke, Secretary, Chief Financial Officer, Director; Dr. Sylvain Fleury, Ph.D., VP, Chief Scientific Officer; Prof. Marc Girard, DVM, D.Sc., Head of Vaccine Development, Chairman of the Scientific Advisory Board |
| |
|
|
|
|
|
|
|
| Keywords |
| vaccine, hiv, aids, HIVAIDS |
|
|
|
| Description |
|
Mymetics is an international biotechnology company focused on developing vaccines and therapies to combat AIDS. Mymetics employs an efficient research strategy. Instead of incurring high fixed costs to maintain its own staff and research facilities, Mymetics organizes and manages a network of public and private research teams, each of which has its own unique focus, while retaining all intellectual property rights on the joint research results. |
|
| Products / Services |
Their vaccine strategy is based on the use of the gp41 molecule, which is a key viral membrane protein required for the penetration of HIV into the host cells.
|
|
| Technology / Differentiation |
| Current drug treatments in HIV focus on slowing or impeding the progress of the virus once it has infected the body's host cells. Newer approaches seek to develop therapies that prevent the virus from fusing with host cells. If the virus cannot fuse, it cannot enter inside the cell and reproducethereby facilitating the successful fight of the body's immune system against the invasion. |
|
| Market / Customers |
Patients suffering from HIV and AIDS.
|
|
| Strategy |
Research has immediate implications for the development of treatments to disarm retroviruses like HIV. It also has applications for other retroviruses often associated with leukemia. Mymetics primary focus in the short term is to develop preventive vaccines for HIV infection. They are also pursuing the development of therapeutic proteins and protein fragments that block HIV from fusing to host cells based on our fundamental understanding of molecular "mimicry."
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
